Business

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.

Know the Business

SKC is not a specialty chemicals company; it is a South Korean holding company that owns four unrelated material businesses plus a 45% stake in a separately-listed semiconductor test-socket maker. The consolidated 2025 operating loss of $210M obscures the only fact that matters for valuation: one of the four pieces (ISC, semi materials) is a high-margin AI-leveraged business worth more on its own than the rest of the group combined, and the market is partway to recognising that. Read SKC consolidated and you misvalue it; read it as a sum-of-the-parts and the investment question becomes specific and tractable.

1. How This Business Actually Works

SKC is four economic engines bolted together, run from a parent shell with debt. Three of them are wholly-owned operating subsidiaries; one (ISC) is a 45.03%-owned listed company that SKC consolidates because of board control. The four engines have nothing in common — different customers, different cycles, different unit economics, different competitors. The parent's job is allocating capital between them. Right now, that means funding losses in copper foil and chemicals while the AI test-socket business prints record results.

The economic point. A $152M-revenue test-socket business produced $41M of operating profit (27% margin) while a $753M chemical business lost $50M. That is not one company having a bad year; it is four different industries showing through the consolidated P&L. Margin doesn't compound across these engines — it averages, badly. The reinvestment runway also doesn't transfer: ISC cannot absorb the capital that copper foil needs, and copper foil cannot use ISC's AI-driven volume growth. The parent moves capital between segments, takes on debt to do it, and earns whatever spread remains after segment-level operating drag and corporate cost.

Read the contrast. The opportunity sits in valuing the parts separately rather than averaging them — the only path that lets the small profitable engine carry weight against the larger drags.

2. The Playing Field

There is no single peer for SKC because SKC sits in three industries. The only honest peer set is one that breaks the company into its parts and finds an economic substitute for each. The multiples below show why this matters: the spread between LEENO (test sockets) and Lotte Chemical (commodity petchem) is more than 30× on EV/EBITDA — the same $1M of revenue is worth a wildly different amount depending on which engine it came from.

Where SKC sits in the spread. SKC trades at 2.6× EV/Revenue — between Lotte Chemical (0.6×) and Hansol Chemical (3.6×) — which would be roughly fair if SKC were just chemicals. It is well below LEENO's 21.9× even though SKC owns 45% of ISC, the test-socket market leader. This gap is the entire SOTP argument: the market discounts the consolidated entity at near-petchem multiples even though the cleanest profit engine inside it deserves test-socket multiples.

The picture. Profitable specialty names (LEENO, Hansol Chemical) sit upper-right. Cyclicals at trough sit lower-left. SKC is anchored bottom-left — paying chemicals/foil multiples for a portfolio that contains one of the upper-right businesses through its ISC stake. The investment question is whether the rest of the portfolio is worth less than zero, or whether the market has correctly identified that the ISC stake is being diluted by the rest.

What "good" looks like in this peer set. Hansol Chemical is the cleanest comparable for what a specialty Korean chemicals business should earn at scale: 24% EBITDA margin, mid-teens ROE, profitable through every cycle since 2010. SKC ran a 19.6% operating margin in 2021, which proves the assets can earn — but it has not put two consecutive profitable years together since. The peer that flatters SKC is LEENO; the peer that judges SKC honestly is Hansol Chemical.

3. Is This Business Cyclical?

SKC is exposed to three uncorrelated cycles, which is both the curse and the option. The cycles do not net to "diversification" — they net to "no single positive catalyst rescues the consolidated number." Recovery in copper foil alone leaves the chemical drag; recovery in chemicals alone leaves the foil drag; semi materials alone are too small to absorb either. Two of three need to inflect together.

The 2021 peak vs 2025 trough. Peak operating income ($331M in 2021) coincided with high copper-foil processing fees, peak EV demand growth, and pre-Chinese-capacity-glut petrochem spreads. The trough since 2023 reflects: (1) 50%+ Chinese copper-foil capacity additions collapsing processing fees from roughly $8/kg to under $4/kg; (2) PG/PO/SM spreads near zero on Chinese cracker over-build; (3) front-loaded Absolics and SK leaveo investment with no offsetting revenue. None of these is a company-execution failure — they are textbook commodity cycles. The asymmetry is that two of the three are commodity cycles that revert; one (semi materials) is a structural growth business that has just begun.

The 1Q26 read-through. Three things happened simultaneously: the test-socket business posted another record (+236% YoY operating profit on AI demand), the chemical segment swung to a small profit on Middle East supply disruption widening PG/SM spreads, and copper foil narrowed losses on ESS volume (+390% YoY North America). For the first time since 2Q23, consolidated EBITDA went positive. It is not yet a cycle inflection; it is a single quarter where two of the three cycles moved together. That is the conditions test for the rest of the year. If chemical spreads hold and ISC keeps growing, the consolidated number can return to break-even on its own without a copper-foil recovery.

Where each cycle hits the P&L first. In copper foil, volume and utilization move first, then processing fee, then margin. In test sockets, the cycle starts at customer wafer-starts and HBM mix — leading SKC's reported revenue by a quarter. In chemicals, spreads can flip negative within a quarter and recovery requires regional plant closures (slow). The investor's job is to watch these leading indicators in exactly that order.

4. The Metrics That Actually Matter

The standard ratios — operating margin, ROE, asset turnover — describe the consolidated past. They do not describe what is about to happen, because they blend three industries together. Below are the few metrics that actually drive value creation and failure here.

Why these and not standard ratios. Operating margin tells you that 2025 was a loss year — it does not tell you which engine is recovering or by how much. The ISC HBM mix is the single best leading indicator of segment value because it directly maps to ASP and to the multiple LEENO trades at. The copper-foil processing fee is the only metric that moves the largest loss-making segment toward break-even — watch the fee, not the volume. The PG/SM spread is the chemical segment's entire P&L in one number. Net debt / equity is the cycle-cushion metric: at 70.0% debt-to-assets in FY25 (vs 63-65% in 2020-2023), SKC is approaching the point where the parent would need to fund growth from new equity — which is why a rights offering was announced for June 2026 and roughly $616M of asset rebalancing was disclosed in 4Q25.

Reading the balance-sheet pressure. Equity attributable to parent fell from $1,663M in 2020 to $574M in 2025 — book value collapsed by more than half during the trough. The rights offering scheduled for June 2026 is a direct response: the parent is rebuilding equity to keep capex flowing through copper-foil ramp and Absolics qualification without breaching covenants. The investor watching debt/equity has 1-2 quarters of warning before any further capital action; the investor watching consolidated operating income gets blindsided.

5. What Is This Business Worth?

SKC must be valued sum-of-the-parts. Consolidated multiples are misleading because the parts have different multiples by an order of magnitude, and one of them is separately listed. A reader who says "SKC is loss-making, therefore EV/Revenue at 2.6× is fair against chemicals peers" is missing the only point that matters: SKC owns 45.03% of a publicly-traded test-socket maker (ISC, KOSDAQ:095340) whose own market cap is $3,652M — meaning the ISC stake alone is worth roughly $1,644M against SKC's $4,117M total market cap.

The two valuation questions, restated.

First — is the ISC mark sustainable? ISC trades at 95× trailing P/E and roughly 22× the implied EV/Revenue of LEENO (its closest pure-play). That premium is paid for AI/HBM design-in lock and rapid revenue growth (semi materials operating profit grew 35% in FY25, with management guiding 20%+ in FY26). If the AI capex cycle holds, the ISC stake holds value. If AI capex disappoints — or if Samsung/SK hynix HBM growth slows materially — the ISC mark is the first thing to compress, and SKC compresses with it. The single biggest risk in this stock is not SK nexilis, it is ISC's own multiple.

Second — what is everything else worth? Stripping the ISC stake from SKC's market cap leaves about $2.5B of "implicit value" that the market is paying for SK nexilis + SK picglobal + Absolics + SK leaveo, less the share of consolidated net debt that sits outside ISC. SK nexilis at replacement cost or trough through-cycle is plausibly worth $400-700M. SK picglobal at trough peer multiples is worth $200-350M. Absolics is the option — anywhere from $0 (loses the qualification race to Samsung 2027) to $700M+ (named NVIDIA/Google customer). The implied number is consistent with copper foil getting credit for replacement value and Absolics being valued near zero — which is fair given that no commercial qualification has been announced.

What would support a premium. Two paths, in order: (1) a named hyperscaler qualification at Absolics that re-rates the glass-substrate option from "if" to "when"; (2) ~30% recovery in copper-foil processing fees that moves SK nexilis from a $120M annual operating loss toward break-even. What would justify a discount. ISC's multiple compressing on AI capex disappointment; the rights offering diluting more than expected; chemical spreads staying near zero; or a second capital action becoming necessary.

6. What I'd Tell a Young Analyst

Three things, in order.

One — value the parts before reading the consolidated number. Mark the ISC stake at the daily KOSDAQ price; everything else can wait. If you skip this step, you will misvalue SKC by half. The single most important number on the SKC tearsheet is not consolidated revenue or operating loss — it is ISC's market cap and SKC's stake percentage.

Two — the leading indicator hierarchy is fixed and short. ISC's quarterly HBM/large-area socket mix tells you about the test-socket franchise before the segment number prints. The copper-foil processing fee tells you about SK nexilis before the loss prints. The PG/SM spread tells you about chemicals before the spread compresses or recovers. Net debt/equity tells you about parent capacity before a capital raise. Watch these four; ignore consolidated EPS.

Three — the asymmetry is in the option, not the cycle. The cyclical recovery in copper foil and chemicals is path-dependent and slow; the AI/HBM growth at ISC is already happening; the glass-substrate optionality at Absolics is binary. The thesis that justifies owning SKC is some combination of "ISC keeps compounding" and "Absolics qualifies first." The thesis that justifies avoiding SKC is "ISC's multiple compresses while the rights offering dilutes." There is no middle case where consolidated metrics matter. Think in parts, not in totals — that is the only way this stock pays you.